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Endothelin-1 (ET-1), released by vascular endothelial cell (EC) and inner medullary collecting duct cells (and other 
cells under pathological conditions), stimulates endothelinA 
(ETA) and endothelinB (ETB) receptor subtypes.1,2 ETA are 
present on vascular smooth muscle cells (VSMCs), predomi-
nantly mediating contraction3 and regulating blood pressure 
(BP).4 They also influence mitogenesis,5 generation of reac-
tive oxygen species, and adhesion molecule expression.6,7 ETA 
receptors on leucocytes mediate cytokine release and cellular 
chemotaxis.8 Many of these processes contribute to vascular 
remodeling, and ET-1 clearly drives arterial lesion formation 
(including neointimal proliferation after injury).7 This can be 
inhibited by selective ETA antagonism.9,10
Regulation of arterial function, BP, and arterial lesion for-
mation by ETB receptors is likely to be more complex because 
they are expressed in EC, VSMC, and the kidney where they 
mediate physiologically antagonistic responses. ECETB recep-
tors mediate production of vasodilator, antiproliferative, and 
anti-inflammatory molecules (eg, nitric oxide [NO])11,12; clear-
ance of ET-1 from the circulation13,14; and regrowth of damaged 
Abstract—The role of smooth muscle endothelinB (ETB) receptors in regulating vascular function, blood pressure (BP), and 
neointimal remodeling has not been established. Selective knockout mice were generated to address the hypothesis that 
loss of smooth muscle ETB receptors would reduce BP, alter vascular contractility, and inhibit neointimal remodeling. ETB 
receptors were selectively deleted from smooth muscle by crossing floxed ETB mice with those expressing cre-recombinase 
controlled by the transgelin promoter. Functional consequences of ETB deletion were assessed using myography. BP was 
measured by telemetry, and neointimal lesion formation induced by femoral artery injury. Lesion size and composition 
(day 28) were analyzed using optical projection tomography, histology, and immunohistochemistry. Selective deletion 
of ETB was confirmed by genotyping, autoradiography, polymerase chain reaction, and immunohistochemistry. ETB-
mediated contraction was reduced in trachea, but abolished from mesenteric veins, of knockout mice. Induction of ETB-
mediated contraction in mesenteric arteries was also abolished in these mice. Femoral artery function was unaltered, and 
baseline BP modestly elevated in smooth muscle ETB knockout compared with controls (+4.2±0.2 mm Hg; P<0.0001), 
but salt-induced and ETB blockade–mediated hypertension were unaltered. Circulating endothelin-1 was not altered in 
knockout mice. ETB-mediated contraction was not induced in femoral arteries by incubation in culture medium or lesion 
formation, and lesion size was not altered in smooth muscle ETB knockout mice. In the absence of other pathology, 
ETB receptors in vascular smooth muscle make a small but significant contribution to ETB-dependent regulation of BP. 
These ETB receptors have no effect on vascular contraction or neointimal remodeling.  (Hypertension. 2017;69:275-285. 
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EC.15 VSMC ETB can mediate vascular contraction, similar to 
the ETA subtype,16 and may compensate for ETA receptor dys-
function.17 ETB upregulation in VSMC may mediate vasocon-
striction and proliferation in cardiovascular disease.18,19
ETB-dependent regulation of BP is demonstrated by the 
sustained hypertension caused by ETB receptor antagonism 
in mice.20 The importance of receptor distribution in this 
response is indicated by increased BP after deletion of ETB 
receptors in the renal collecting duct21 but not after deletion 
of ECETB.22 The influence of VSMC ETB on BP has not been 
established but, given their potential to mediate vasoconstric-
tion, deletion or antagonism of VSMC ETB would be pre-
dicted to reduce BP.
Despite the influence of ET-1 in vascular remodeling,23 
the role of ETB is less clear. ETB activation in EC (NO release) 
and kidney (reduced BP) would be predicted to inhibit arterial 
remodeling, thus favoring selective ETA antagonism for reducing 
neointimal proliferation.9 Certainly, global deletion of ETB recep-
tors increases vascular lesion size.10,24 However, selective ECETB 
deletion did not influence lesion formation, suggesting that the 
protective role was mediated by ETB receptors in other tissues.9 
If ETB receptors in VSMC contribute to lesion formation, mixed 
ETA/B antagonists might have advantages over ETA selective com-
pounds, although recent investigations9,10,24 favor the latter.
We generated novel smooth muscle ETB receptor knock-
out (SMETB KO) mice to address the hypothesis that loss of 
these receptors would impair arterial contraction, lower BP, 
and reduce neointimal lesion formation in response to vascu-
lar injury.
Methods
Mice with VSMC-selective ETB receptor deletion were generated 
by crossing homozygous floxed ETB mice with SM22cre transgenic 
mice, which express cre-recombinase in the heart and smooth muscle, 
(then backcrossed to a C57Bl/6J background for 4–6 generations), as 
described for ECETB KO.22 Controls were Cre-negative littermates (ETBf/f). Genotyping was performed using ear clips.22,25 Wild-type (WT) C57Bl/6J mice were from Charles River (United Kingdom). 
Mice were housed according to the UK Home Office recommen-
dations (22°C; 12-hour light/dark cycles) with free access to water 
and chow. Procedures were performed under the provisions of the 
Animals Scientific Procedures Act (1986) and approved by the local 
Ethics Committee.
Selective SMETB deletion was demonstrated in organs and in iso-
lated aortic smooth muscle cells (SMCs) using polymerase chain re-
action, autoradiography,14,26 immunohistochemistry,27 and functional 
(myographic) investigation of isolated trachea, arteries, and veins.28,29
The impact of SMETB KO on BP was assessed using radioteleme-
try22 in conscious, unrestrained male SMETB KO mice and age-matched 
controls (n=8 per group), fed on chow (7 days), high (7.6%) salt diet 
(7 days), then high salt plus ETB antagonist (SB192621; 30 mg−1 kg−1 
day−1 in drinking water, 7 days). ET-1 concentrations in plasma from WT 
C57Bl/6J, controls, and SMETB KO were measured after exposure to 
chow or to high salt diet plus ETB antagonist, by ELISA (Endothelin-1 Quantikine ELISA kit; R&D Systems, Oxford, United Kingdom).
Intraluminal (left) or nondenuding (right) femoral artery injury 
was achieved by insertion of an angioplasty guidewire or ligation, re-
spectively, as described.9 After 28 days, arteries were retrieved (after 
perfusion fixation) and analyzed using optical projection tomography, 
histology, and immunohistochemistry.9,30
Statistics
Results are mean±SEM, for n mice. Group sizes were chosen to detect 
5%, 20%, and 20% differences in BP (n=7), lesion size (n=7), and 
maximum responses to vasoactive agents (n=6) with >90% power. 
Investigations were performed by operators blinded to treatment. 
Components of lesions were expressed as a percentage of the neo-
intimal area. Analyses were performed with GraphPad Prism using 
Student t test, 1-way or 2-way ANOVA with a Tukey post hoc test, as 
indicated. Significance was assumed for P<0.05.
Detailed methods are in the online-only Data Supplement.
Results
Identification of SMETB KO
Genotyping for SM22cre, WT, and delta band alleles 
(Figure 1A) identified SMETB KO (positive for SM22cre, 
floxed, and delta band and negative for WT allele) and con-
trols (SMETBf/f cre-negative littermates; negative for WT 
allele, positive for floxed allele, and negative for SM22cre and 
delta band). SMC isolated from the aorta of SMETB KO mice 
expressed the cre, delta, and flox bands, whereas controls did 
not express the cre and the delta bands (Figure 1B).
Autoradiography (Figure 1C) identified ETB receptors in 
the gut lining, lung, and kidney. This signal was not dimin-
ished after SMETB deletion. ETB expression (real-time poly-
merase chain reaction) was not altered in the colon, heart, or 
gastrocnemius muscle of SMETB KO mice (Figure S1 in the 
online-only Data Supplement). Confocal imaging of immu-
nofluorescence (Figure 1D) clearly showed ETB receptors 
localizing to the endothelium (von Willebrand factor positive) 
in SMETB KO coronary artery. ETB staining in medial SM 
remained at background levels. This confirms maintained ETB 
receptor expression in the endothelium of SMETB KO mice.
Functional Confirmation of SMETB KO
SMETB KO mice were healthy with normal body and organ 
weights (Table S1).
Sarafotoxin S6c (S6c)–mediated contraction in tracheas 
(which express ETB receptors on SM)22 from controls was 
abolished by incubation with the selective ETB antagonist 
A192621 (Figure 2A).22 In SMETB KO mice, S6c-mediated 
contraction was reduced (≈30%), but not abolished. The 
residual contraction was blocked by ETB antagonism. S6c-
mediated contraction of mesenteric veins was abolished by 
selective deletion of SMETB (Figure 2B).
SMETB KO and BP
Control and SMETB KO mice demonstrated a clear diurnal 
rhythm in BP (Figure 3A). Mean 24-hour BP was higher in 
SMETB KO mice than in controls (107.1±0.3 versus 102.8±0.5 
mm Hg; n=7; P<0.0001; Figure 3B). Systolic BP was not different 
between groups (123.5±0.6 versus 124.8±0.5 mm Hg; P=0.09; 
Figure 3C), but SMETB KO mice had an increased diastolic BP 
(98.2±0.3 versus 92.2±0.4 mm Hg; P<0.0001; Figure 3D). BP 
elevation occurred despite reduced heart rate (515±3 versus 
538±5 bpm; P=0.004; Figure 3E). High salt increased BP in 
controls with a further increase induced by ETB antagonism 
(Figure 4A). These responses were similar in SMETB KO.
SMETB KO and Circulating ET-1
Plasma ET-1 concentrations were similar in SMETB KO and 
control mice (Figure 4B) and consistent with levels in WT 
C57Bl/6J (1.14±0.08; n=6). The combination of high salt diet 
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A
C
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B
Figure 1. Selective endothelinB (ETB) receptor deletion from smooth muscle. A, Mice were genotyped for (i) SM22cre (band at 500 bp), (ii) 
wild-type (band a 500 bp), and (iii) flox (band at 1171 bp)/delta (band at 259 bp) alleles in ear clip DNA. (i) Samples 1 and 2 are cre-positive, 
(ii) sample 4 is positive for the wild-type allele; samples 3 and 5 are not, (iii) samples 7 and 8 are positive for both the flox (Continued )
 by guest on January 19, 2017
http://hyper.ahajournals.org/
D
ow
nloaded from
 
278  Hypertension  February 2017
and ETB antagonism increased plasma ET-1 to a similar extent 
in control-type and SMETB KO mice (Figure 4C).
SMETB KO and Neointimal Remodeling
Wire injury of the left femoral artery generated neointimal 
lesions (Figure 5A).9 Optical projection tomography dem-
onstrated that SMETB KO altered neither the lesion vol-
ume (Figure 5B) nor cross-sectional narrowing (Figure 5C). 
Histological analysis showed a trend toward reduced cross-
sectional narrowing in SMETB KO (Figure 5D). Ligation of 
the right femoral artery generated lesions9 with similar volume 
(Figure 5E) and maximal cross-sectional area (Figure 5F) in 
SMETB KO mice and control mice.
Immunohistochemistry (Figure S2) showed that SMETB 
KO did not differ from controls in the amount of macrophage 
(Mac-2; SMETB KO 2.7±0.9% versus Control 2.6±0.7% 
lesion area), α-smooth muscle actin (SMETB KO 14.8±4.1% 
versus Control 19.9±3.8% lesion area), or collagen (SMETB 
KO 9.7±3.1% versus Control 14.9±3.2% lesion area) staining 
in the neointimal lesions.
SMETB KO and Vascular Reactivity
In WT C57Bl/6J mice, EC removal from aortic rings abol-
ished acetylcholine-mediated relaxation and enhanced the 
contractile response to phenylephrine but not to ET-1. EC 
removal from femoral arteries also abolished acetylcholine-
mediated relaxation but had no effect on phenylephrine or 
ET-1 (Figure S3; Table S2). SMETB KO had no effect on con-
tractile responses to phenylephrine or ET-1, or acetylcholine-
mediated relaxation in femoral arteries (Figure S4; Table S3).
Induction of ETB-Mediated Contraction in Isolated 
Mesenteric Arteries
ET-1–mediated contraction in mesenteric arteries from WT 
C57Bl/6J mice was shifted to the right by mixed ETA/B, or 
selective ETA, antagonism, but not by ETB selective antagonism 
(Figure S5; Table S4). Unlike mesenteric veins (Figure 6A), 
mesenteric arteries freshly isolated from WT C57Bl/6J mice 
did not contract in response to S6c (Figure 6B).
Incubation in culture medium (≤5 days) can induce ETB-
mediated contraction in rat arteries.29 Incubation of C57Bl/6J 
mesenteric veins in culture medium had no effect on S6c-
mediated contraction (Figure 6A). In mesenteric arteries, incu-
bation in culture medium selectively increased the contractile 
response to ET-1 (Table S5). Strikingly, S6c-mediated contrac-
tion was induced in isolated mesenteric arteries after incubation 
in culture medium (Figure 6B; Table S5), a response abolished 
by selective ETB, or mixed ETA/B, antagonism, but not by selec-
tive ETA antagonism (Figure 6C; Table S6). Incubation of mes-
enteric arteries from SMETB KO mice in culture medium did 
not induce S6c-mediated contraction (Figure 6D).
No Induction of ETB-Mediated Contraction in 
Femoral Arteries
S6c-mediated contraction was variable in femoral arteries 
from WT C57Bl/6J mice: some contracted but others did not 
(Figure 6E). Neither incubation of femoral arteries in culture 
medium (24 hours; Figure 6F) nor lesion formation induced 
S6c-mediated contraction; femoral arteries isolated 28 days 
after ligation contracted in response to ET-1 (Figure 6G) but 
not to S6c (Figure 6H). Responses to acetylcholine, sodium 
A
B
Figure 2. Functional consequences of selective endothelinB (ETB) 
deletion from smooth muscle (SM). A, Sarafotoxin S6c (S6c)-
induced contraction of isolated trachea was abolished by ETB 
receptor antagonism (A192621; 100 nmol/L) but only reduced by 
selective smooth muscle ETB receptor (SMETB) deletion (residual 
contraction was blocked by A192621). Columns are mean±SEM 
(n=4). *P<0.02, **P<0.005. B, S6c-induced contraction in murine 
mesenteric veins was abolished by SMETB deletion. Symbols 
represent mean±SEM (n=4). *P<0.05, **P<0.01. KO indicates 
knockout; and KPSS, potassium physiological salt solution.
Figure 1 Continued. and the delta band; sample 6 has only the flox band. B, Polymerase chain reaction (PCR) for cre and flox/delta 
bands in murine aortic smooth muscle cells isolated from smooth muscle ETB receptor knockout (SMETB KO) and control (C) mice. 
Control mice lacked cre and delta alleles, whereas SMETB KO expressed all 3. Standard DNA ladders have band sizes 1500–100 bp. 
C, Autoradiography showing maintained ETB ligand binding in SMETB KO lung and kidney (representative of n=3 mice/genotype). D, 
Confocal images of a coronary artery from an SMETB KO mouse stained for (i) ETB receptor (green) or (ii) the endothelial cell marker von 
Willebrand factor (vWF; red). Merged images (iii) show clear colocalization of ETB with the endothelium (arrows). There is no ETB staining 
in medial smooth muscle. Scale bar=50 µm. +Ve, positive control; –Ve, negative control; ETA indicates endothelinA; H, heart; K, kidney; L, 
liver; Lu, lung; and NSB, nonspecific binding.
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nitroprusside, and phenylephrine were unaltered by lesion for-
mation (Figure S6).
Discussion
Tissue-specific knockout mice were generated to address 
the hypothesis that selective deletion of ETB receptors from 
VSMC would impair arterial contraction, lower BP, and 
reduce neointimal lesion size. SMETB KO attenuated S6c-
mediated vascular and tracheal contraction, without alter-
ing other functional responses, but produced a modest (≈4 
mm Hg) increase in BP. ETB-mediated contraction was not 
induced in femoral arteries after ligation, although injury-
induced intimal lesion formation was unaffected by SMETB 
KO. Key findings are summarized (Figure S7) and compared 
with the ECETB KO (Table S7).
SMETB KO was based on our generation of ECETB KO,22 
crossing mice expressing Cre-recombinase controlled by the 
SM-specific SM22 promoter25 with those bearing a floxed 
ETB gene.22 This strategy was used to produce mice with 
SM-selective ETA deletion,4 and renal collecting duct–selective 
A B
C
E
D
Figure 3. Selective deletion of endothelinB (ETB) receptors from smooth muscle increases baseline blood pressure (BP). A, BP, assessed in 
conscious, unrestrained male smooth muscle ETB receptor knockout (SMETB KO) mice and controls (n=8 per group) using radiotelemetry, 
demonstrated a clear diurnal rhythm. Mean blood pressure (MBP) in SMETB KO (filled symbols) mice was consistently higher than 
controls (open symbols). B, Data averaged over 24 h confirmed elevated MBP in SMETB KO, with no difference in (C) systolic blood 
pressure (SBP) but (D) elevated diastolic blood pressure (DBP). E, Increased MBP was accompanied by reduced heart rate. Data are 
mean±SEM (n=8 per group). **P<0.005, ***P<0.0001. D indicates day; and N, night.
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ETB deletion.21 It has also been used within our group to pro-
duce mice with SM-selective deletion of glucocorticoid recep-
tor31 or 11β-hydroxysteroid dehydrogenase 132 (with LacZ 
staining in Rosa26 reporter mice showing SM22cre expression 
in the blood vessels and heart but not in the brain, kidney, or 
adrenal gland). As with ECETB KO,22 SMETB KO mice were 
healthy. This contrasts with global ETB deletion, which causes 
coat spotting and death from megacolon,33 requiring transgenic 
ETB rescue in the enteric nervous system.34 Autoradiographic 
detection of ETB receptors in lungs of SMETB KO mice indi-
cates maintained expression in EC (which was lost in ECETB 
KO).14 This was supported by colocalization of immunoreac-
tivity for ETB with an EC marker (von Willebrand factor) in 
coronary arteries; absence of medial ETB staining was consis-
tent with deletion from SMCs. Polymerase chain reaction con-
firmed that ETB had been deleted from aortic smooth muscle 
but not from heart, colon, or skeletal muscle (although direct 
evidence of ETB deletion from tracheal, mesenteric vein, 
A
B
Figure 4. Selective deletion of endothelinB (ETB) receptors from smooth muscle does not alter blood pressure (BP) responses. A, BP, 
assessed in conscious, unrestrained male smooth muscle ETB receptor knockout (SMETB KO) mice and controls (n=8 per group) using 
radiotelemetry (i) was elevated by high salt diet (HS; 7 d) and by ETB antagonism (A192621; 30 mg
−1 kg−1 d−1; 7 d) in both groups. (ii) 
Comparison of BP (averaged over 24 h) demonstrates the elevation in mean blood pressure (MBP) in response to high salt diet and high 
salt diet plus A192621. (iii) There was no difference in systolic blood pressure (SBP) in control compared with SMETB KO mice but (iv) 
diastolic blood pressure (DBP) was higher in SMETB KO for all treatment groups. B, Plasma endothelin-1 (ET-1) concentrations were similar 
in SMETB KO and controls and consistent with wild-type C57Bl/6J mice (1.14±0.08 pg/mL; n=6). ET-1 concentrations were elevated in 
control and SMETB KO mice after exposure to a high salt diet plus A192621. Data (mean±SEM) were analyzed using 2-way ANOVA with 
Tukey or Bonferroni post hoc test, as appropriate. A, *P<0.05, **P<0.01 compared with controls. B, ****P<0.00001 (effect of diet).
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mesenteric, or femoral artery smooth muscle was not obtained 
using this technique). Functional investigations confirmed 
that SMETB-dependent responses were lost in the knockout, 
with the abolition of S6c-mediated contraction in mesenteric 
veins. Furthermore, induction of S6c-mediated contraction 
in mesenteric arteries incubated in culture medium (as in rat 
A
B
D
E F
C
Figure 5. Selective smooth muscle endothelinB (SMETB) deletion does not alter neointimal lesion formation. A, Wire injury–induced lesion 
formation in femoral arteries from control and SMETB knockout (KO) mice. Neointimal lesion volume (B) and maximal cross-sectional 
area (C) were similar in control and SMETB KO mice when measured by optical projection tomography. Similar results were obtained 
when maximal cross-sectional area was measured histologically (D). Volume (E) and maximal cross-sectional area (F) of lesions induced 
by ligation were similar in control and SMETB KO mice (optical projection tomography [OPT]). Data are mean±SEM (n=7). EEL indicates 
external elastic lamina; IEL, internal elastic lamina; L, lumen; and NI, neointima.
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A B
C D
E F
G H
Figure 6. Impact of smooth muscle endothelinB (SMETB ) receptors on vascular function. A, Sarafotoxin S6c (S6c)-induced contraction  
in mesenteric veins (n=6) was not increased by incubation for 1 (n=3) or 5 (n=1) d in culture. B, Freshly isolated mesenteric arteries (n=6) 
did not respond to S6c, but contractions were induced by incubation in culture medium for 1 (n=7) or 5 (n=3) *P<0.05, (Continued )
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arteries35), was abolished by SMETB KO (although these func-
tional changes do not necessarily confirm selective SMETB 
deletion). The failure to abolish S6c-induced contraction in 
trachea was unexpected and suggests either incomplete pen-
etrance of SM22cre-mediated recombination or a role for 
ETB receptors in other cells (eg, epithelium) in mediating 
tracheal contraction. Detection of the delta band in some ear 
clip samples may suggest deletion of the floxed gene in germ 
cells, which is a possible limitation with these mice. However, 
our F+/Cre0×F+/Cre0 crosses did not produce piebald mice 
(which inevitably would occur if germ-line recombination 
takes place). Therefore, the delta band during genotyping 
can only be explained by the presence of SMC in the ear clip 
preparations.
Selective deletion of ETB from EC increased plasma 
ET-122 because of impaired clearance.14 In contrast, SMETB 
KO did not alter circulating ET-1, consistent with the proposal 
that ECETB predominantly mediate ET-1 clearance.
Transgenic and pharmacological approaches suggest ETB 
receptors regulate BP. Selective ETB receptor antagonism,20 
global ETB deletion,10 and selective ETB deletion from the col-
lecting duct21 all increased (≈10–13 mm Hg) BP. Furthermore, 
ETB receptors in peripheral ganglia can influence BP,36 sug-
gesting that sympathetic activation accounts for ETB-induced 
hypertension.37 In contrast, BP was not elevated by ECETB 
KO.22 The small (≈4 mm Hg) increase in BP, which persisted 
in SMETB KO mice despite reduced heart rate, suggests that 
loss of SMETB contributes to the increased BP induced by 
systemic ETB antagonism20 or global ETB deletion.10 However, 
it requires rejection of our hypothesis that ETB-mediated vas-
cular contraction contributes to BP elevation. Indeed, our 
data support a role for extravascular ETB (eg, in the kidney or 
peripheral ganglia) in regulating BP. This is supported by the 
demonstration that, as in ECETB KO,22 salt-induced and ETB 
antagonist–induced elevations of BP are unaltered by SMETB 
KO. The mechanism underlying increased BP after SMETB 
KO is not apparent but is unlikely to be a consequence of cre 
overexpression in SM because this did not alter baseline BP in 
SMETA KO mice.4 Several possible explanations can be pro-
posed. First, ETB in VSMC may contribute to the clearance of 
ET-1 from tissue where it is preferentially secreted by EC, and 
where it acts. Therefore, SMETB KO may cause ET-1 accu-
mulation in the vascular wall, thus increasing ET-1–mediated 
vasoconstriction. Second, loss of SMETB may upregulate ETA-
mediated contraction. Third, SMETB in the kidney may influ-
ence sodium homeostasis. Because SM22 may be expressed 
in perivascular fat precursors,36 loss of ETB from perivascu-
lar fat may have caused developmental changes in vascular 
function that also contribute to elevated BP, but this has not 
been established. It is also not clear why basal diastolic blood 
pressure is selectively increased in the SMETB KO, but this 
would be worthy of future investigation.
Increased BP in SMETB KO mice could not be attributed 
to vascular dysfunction as, with the exception of responses to 
S6c, we found no evidence of impaired arterial relaxation or 
contraction. Weak ETB–mediated contraction in arteries is con-
sistent with studies in rats.35 Preliminary investigations (unpub-
lished data) indicated that S6c-induced contraction of freshly 
isolated murine arteries (femoral, mesenteric, and carotid) 
was not increased by NO synthase inhibition or by removal 
of the endothelium. These results indicate that we are not 
missing an ETB-mediated contraction that has been obscured 
by ETB-mediated relaxation. Induction of ETB-mediated con-
traction after incubation has been attributed to transcriptional 
regulation and MEK-ERK1/2 signaling.22,38 Abolition of this 
response in mesenteric arteries from SMETB KO mice indi-
cated that they lack both functional arterial ETB receptors and 
the means to generate new receptors in this tissue.
ETB upregulation in SMC, mediating vasoconstriction and 
proliferation in cardiovascular disease,18,19 might explain stud-
ies reporting similar benefit from mixed ETA/B and selective 
ETA antagonism in reducing lesion formation23,39,40 (despite the 
protective roles of ETB in several tissues, eg, EC and kidney). 
However, the effectiveness of mixed ETA/B and selective ETA 
antagonism is likely to depend on the balance of ETB recep-
tor activity in EC and VSMC of an affected artery. Transient 
upregulation of ETA and ETB receptors has been demonstrated 
in arterial lesions.41 If these ETB receptors contribute to lesion 
formation, then ETB antagonism would be desirable. There 
was, however, no evidence of induced ETB-mediated contrac-
tion in mouse femoral arteries after ligation. Similar investiga-
tions could not be performed after wire injury because these 
vessels fail to contract ex vivo. It remains possible that ETB 
upregulation occurs in other (eg, carotid) arteries.
Neointimal lesion formation is increased in rescued global 
ETB knockout mice10 and in (spotted lethal) rats with global 
deletion of ETB,24 consistent an antiproliferative role for ETB 
receptors. This is supported by demonstrations that ETB recep-
tor antagonism increases lesion size,9,24 with the suggestion 
that this is because of impaired ETB–mediated release of NO 
from EC. Indeed, increased lesion formation in mice with 
global ETB deletion was partly attributed to impaired EC–
derived NO release.9 In contrast, selective ECETB deletion 
inhibited ETB-mediated relaxation22 but had no effect on arte-
rial lesion formation.9 These results suggest, therefore, that 
the protective role of ETB receptors is played by non-ECETB 
receptors. The demonstration here that deletion of ETB from 
the SMC does not alter lesion size indicates that, as with the 
receptors in EC,9 ETB in SMC do not influence neointimal 
remodeling. This implicates nonvascular ETB receptors, for 
Figure 6 Continued. **P<0.01, ***P<0.005 compared with d 0. C, S6c-mediated contraction of mesenteric arteries after 24 h in culture 
(n=7) was abolished by ETB selective (A192621; 100 nmol/L; n=3) or mixed ETA/B (BQ-123+A192621; n=3) antagonism, but not by ETA 
receptor antagonism (BQ-123; 100 nmol/L; n=3); **P<0.01, ***P<0.005 compared with ETB or ETA/B antagonism; #P<0.05, ###P<0.005 
compared with vehicle. D, In contrast to controls (n=4), S6c-mediated, A192621 (100 nmol/L)-sensitive contraction was not induced in 
mesenteric arteries from SMETB knockout (KO) mice (n=4) by incubation in culture medium (24 h); ***P<0.005, ****P<0.001 compared 
with antagonists. E, Contractile responses to S6c were unreliable in femoral arteries—some failed to contract, whereas others produced 
small contractions. *P<0.05, ***P<0.005, ****P<0.001 compared with nonresponders. F, Incubation in culture did not induce S6c-mediated 
contraction in these arteries. Femoral arteries after ligation (28 d) contracted in response to endothelin-1 (G) but not to S6c (H). Data are 
mean±SEM (n=3 to 6). ETA indicates endothelinA; and KPSS, potassium physiological salt solution.
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example, in monocyte-derived macrophages, in the regulation 
of neointimal proliferation and atherosclerosis.42
In conclusion, we have demonstrated that selective ETB 
receptors in SMC may contribute modestly to regulation of 
BP but have little influence on vascular contraction or neointi-
mal proliferation. These data suggest that any detrimental role 
of SMETB is minor (at least during normal physiology), and, 
therefore, that selective ETA receptor antagonists (which pre-
serve protective EC/renal ETB signaling) should be preferred 
to mixed ETA/B antagonists for treatment of vascular disease.
Perspectives
Generation of mice with selective deletion of ETB from SMC 
indicates that these receptors contribute to the increased BP 
induced by ETB receptor antagonism but do not regulate arte-
rial function or the fibroproliferative response to acute arte-
rial injury. It would be interesting to determine whether ETB 
in SMCs influence other cardiovascular diseases (eg, diabetic 
complications). Whether the data generated in these animals 
are replicated in mice with cardiovascular disease (eg, athero-
sclerosis), or in man, remains to be established. However, these 
results support the proposal that selective ETA receptor antag-
onists may have advantages over mixed ETA/B antagonists for 
combatting elevated BP or restenosis after revascularization.
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What Is New?
•	This study describes newly generated mice with selective endothelinB (ETB) 
receptor deletion from smooth muscle. This was used to clarify the influ-
ence of smooth muscle ET
B
 receptors on (1) blood pressure, (2) arterial and 
venous contraction, and (3) arterial remodeling following injury.
What Is Relevant?
•	Generation of the knockout was necessary because ETB receptors in vas-
cular endothelial and smooth muscle cells cannot be distinguished phar-
macologically. This work shows that ET
B
 receptors in smooth muscle have 
little influence on arterial function or neointimal remodeling but have a 
small suppressive effect on diastolic blood pressure. This is consistent with 
the proposal that selective endothelin
A
 (ET
A
) antagonism would be prefer-
able to mixed ET
A
/ET
B
 antagonism for inhibiting arterial remodeling.
Summary
Selective smooth muscle ET
B
 deletion indicated that these receptors 
play a minor role in regulation of BP but do not affect vascular func-
tion or remodeling. This suggests that, beyond endothelial cell ET
B
, 
ET
B
-dependent regulation of these processes is mediated by recep-
tors in extravascular cells (eg, renal collecting ducts).
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Animals 
Mice with VSMC selective deletion of ETB receptors were generated based on a strategy 
described previously to produce EC ETB KO mice1. Homozygous (Flox/Flox) ETB mice 
(background: 50% 129/Ola and 50% BKW) were crossed with SM22-Cre transgenic mice 
and backcrossed to C57Bl/6J for 4-6 generations. As for previous studies1,2 floxed, Cre-
negative littermates (ETBf/f) were used as experimental controls for SM-specific ETB deficient 
mice (SM ETB KO). Genotyping to identify wild type and recombined alleles was performed 
by PCR1 and the SM22-Cre transgene was detected as described3. All mice were given free 
access to tap water and standard mouse chow. Mice were housed according to United 
Kingdom Home Office recommendations at 22°C with 12-hour diurnal light/dark cycles. All 
procedures were performed under the provisions of the Animals Scientific Procedures Act 
(1986) and with the approval of the local ethics committee. 
Autoradiography 
After euthanasia, SM ETB KO mice and controls (n=3/group) were rapidly frozen at -70oC, 
torsos were mounted in a cryostat and consecutive 30µm longitudinal sections were cut to 
encompass the major thoracic and abdominal organs. Sections were thaw-mounted onto 
gelatin-coated slides4 and ligand binding assays performed as described5. Briefly, consecutive 
sections were incubated with 0.25nM of the ETA selective ligand [125I]PD151242 or 0.25nM 
of the ETB selective ligand [125I]BQ2030 (Amersham Bioscience, GE Healthcare, UK). Non-
specific binding was determined by co-incubating adjacent sections with the ligand and 
corresponding excess unlabelled peptide. Slides with calibrated standards were exposed to 
Kodak MR-1 autoradiography film for 4 days before being developed. 
Immunohistochemistry 
Immunohistochemical identification of ETB receptors was performed as previously 
described6. Site directed antisera were raised in rabbits to the sequence ETB(302-313), as 
described7. Briefly, whole body tissue sections (15 μm) were dried overnight at room 
temperature and fixed in ice-cold acetone for 10 minutes. Three knock-out and three control 
mice were examined.  
Slides were incubated with 5% non-immunised donkey serum (DS) in phosphate-buffered 
saline (PBS) for 1 hour at room temperature to block non-specific protein interactions and 
then incubated overnight at 4 °C with primary rabbit anti-ETB (1:50) antiserum and primary 
goat anti-von Willebrand factor (1:50) PBS/0.1% Tween-20/3% DS. Slides were then washed 
(3×5 minutes) in cold 1% PBS/0.1% Tween-20 before incubation for 1 hour at room 
temperature with Alexa Fluor 488 conjugated donkey anti-rabbit (1:200), Alexa Fluor 568 
conjugated donkey anti-goat (1:100) secondary antibodies and Hoechst (1:100) diluted in 1% 
PBS/0.1% Tween-20/3% DS. Tissue sections were washed again (3×5 minutes) in cold 1% 
PBS/0.1% Tween-20 and mounted with ProLong Gold (Invitrogen). Confocal imaging was 
performed using a Leica TCS-NT-UV confocal laser-scanning microscope (Leica 
Microsystems, Heidelberg,Germany).  
Ex vivo analysis of ETB-mediated contraction 
Functional analyses were performed using isolated mouse trachea, aorta, femoral arteries, and 
1st order mesenteric arteries and veins, as described8. The endothelium was removed from 
some aortic rings by rubbing the luminal surface with a wire. Some arteries and veins were 
incubated in serum-free medium (DMEM) for 1-5 days before functional analysis to induce 
ETB-mediated contraction, after the method of Adner et al.9. Briefly, rings (~2mm in length) 
of trachea, femoral artery, or mesenteric artery or vein were suspended on two intraluminal 
 3 
 
40 µm tungsten wires in a myograph (model 610M Multi-myograph; JP Trading, Aarhus, 
Denmark) chamber.  These rings were equilibrated at their optimum resting force (trachea 
2mN; aorta 7.36mN, femoral artery, 8mN; mesenteric artery 3mN; mesenteric vein, 1mN) in 
physiological salt solution (PSS; 119 mM NaCl, 14.9 mM NaHCO3, 4.7 mM KCl, 1.18 mM 
KH2PO4, 1.17 mM MgSO4, 1.6 mM CaCl2, 0.026 mM EDTA, 5.5 mM glucose), aerated 
(95% O2, 5% CO2) and maintained at 37°C.  Each ring was then exposed to a high potassium 
(125mM) PSS (KPSS.  Cumulative concentration-response curves were obtained to 
phenylephrine (PE, 1x10-9-3x10-3M), ET-1 (1x10-11-3x10-5M), acetylcholine (1x10-9-3x10-
3M) or sarafotoxin 6c (S6c; 1x10-11-3x10-5M), as required. Some rings were incubated with 
an ETA antagonist (BQ123; 100nM), an ETB antagonist (A192621; 100nM) or a mixture of 
the two antagonists 20 min before acquiring cumulative concentration-response curves. All 
responses were measured and recorded with Powerlab software. 
Measurement of BP 
Male SM ETB KO mice and age-matched controls (n=8/ group) were caged singly and 
maintained on standard mouse chow (7 days) before measurement of BP and heart rate using 
telemetry, as described previously1. Briefly, under isoflurane anesthesia, a telemetry catheter 
was inserted into the left carotid artery and the transmitter device (Data Sciences) secured in 
the left flank. Mice were allowed to recover and were maintained on standard chow (7 days), 
high (7.6%) salt diet (7 days), then high salt plus ETB antagonist (SB192621; 30/mg/kg/day 
in drinking water, 7 days). Systolic and diastolic BP and heart rate were recorded in 
unrestrained mice (for 5 min every 30 min) as described previously1 and analyzed using the 
Powerlab data acquisition system. Average blood pressures over each 5 min period (48 
measurements/ day) were used to calculate the 24 h average BP. 
Femoral artery injury 
Intra-luminal injury was performed as described2. Briefly, under inhaled isoflurane 
anaesthesia (induction 5%, maintenance 2-3%) a 0.014” diameter straight-sprung angioplasty 
guide wire was advanced ~1.5cm proximally into the isolated femoral artery through an 
arteriotomy in the popliteal branch. After withdrawal, the popliteal branch was ligated to 
allow re-perfusion of the injured femoral artery. Non-denuding injury was achieved by 
ligation of the right femoral artery at the femero-popliteal bifurcation2. Peri-operative 
analgesia was provided by administration of buprenorphine (0.05mg/kg buprenorphine s.c.; 
Alstoe Animal Health, UK). Mice were then allowed to recover (28 days) to allow lesion 
development. 
Perfusion fixation 
After the recovery period mice were killed by perfusion fixation.  Under terminal anaesthesia 
(sodium pentobarbital, Ceva Animal Health, UK, 60 mg/kg; i.p.), thoracotomy and transverse 
sternotomy were performed to allow introduction of a 23-gauge needle into the left ventricle. 
Phosphate buffered saline containing heparin (Leo Laboratories, UK, 10 U/ml) was 
administered (6 ml/min) via the left ventricle and an incision was made in the right ventricle 
to allow perfusate to wash through. Once blood was washed out, 10% neutral buffered 
formalin (Sigma, UK) was perfused until adequate fixation occurred (indicated by the 
development of rigidity of the body).  Following perfusion fixation, femoral arteries, liver, 
heart and kidneys were removed. Organs were weighed and all tissues were left in formalin 
for a further 48h before processing to paraffin for histological assessment. 
Optical projection tomography 
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Non-destructive 3-dimensional assessment of lesions was performed using optical projection 
tomography (OPT), as described10,11. Briefly, vessels were embedded in agarose and optically 
cleared in benzyl alcohol/ benzyl benzoate. Intrinsic fluorescent emission was imaged 
(excitation filter: 425/40 nm; emission filter: 475 nm low pass) using a Bioptonics 3001 
tomograph. Data were reconstructed by filtered back projection using NRecon software 
(Skyscan, Belgium) and volumetric measurements generated by semi-automated tracing of 
the internal elastic lamina and the neointima distinguished from the lumen using a grey level 
threshold.  
Histological assessment of neointimal lesions 
Sections (4 µm) were cut from paraffin-embedded femoral arteries at 80 µm intervals with a 
Leitz 1512 microtome (Leica microsystems, Germany), and mounted onto Superfrost glass 
slides. Every tenth slide was selected for staining (Shandon Varistain Gemini automated slide 
stainer) with United States Trichrome, as described12.  Images were taken using an Axioskop 
KS300 stage microscope (Carl Zeiss Inc., UK) and a CCD camera (photometrics USA) with a 
liquid crystal filter (MicroColour, LRI, Inc, USA). Image analysis was performed using 
MCID basic 7.0 software (Imaging Research, USA). The location of the maximal lesion was 
determined and serial sections used for compositional analysis, including picro-sirius staining 
for the quantification of collagen content. 
Immunohistochemistry 
De-waxed and re-hydrated sections were blocked with goat serum before incubation with 
primary antibodies to α-smooth muscle actin (1:400; 30 min; Sigma, UK) and Mac2 (1:6000; 
overnight; Cedarlane, USA).  Sections were then washed and incubated with a secondary 
antibody (goat anti-mouse or goat anti-rat, respectively; 1:400, 30 min; Vector Labs, UK).  
This was followed by incubation with streptavidin-conjugated horseradish peroxidase 
Extravidin; 30 min; Sigma, UK).  Slides were developed by addition of 3,3-diaminobenzidine 
(DAB peroxidase staining kit, Vector Lab, UK) for 1 min. Images were taken as before and 
analysed with Image J software. 
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Supplementary Table S1. Deletion of ETB from smooth muscle did not alter body or organ 
weights. 
 
Age & Weights Wild Type SMETB KO 
Age (weeks) 20.0 ± 1.4 20.8 ± 1.6 
Body Weight (g) 31.6 ± 0.8 32.1 ± 0.6 
Heart (% Body Weight) 0.56 ± 0.03 0.56 ± 0.02 
Liver (% Body Weight) 5.08 ± 0.15 4.88 ± 0.18 
Right Kidney (% Body Weight) 0.72 ± 0.03 0.74 ± 0.03 
Right Kidney (% Body Weight) 0.68 ± 0.02 0.71 ± 0.03 
Lung (% Body Weight) 0.54 ± 0.03 0.56 ± 0.02 
Data are mean ± s.e. mean, n=7. 
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Supplementary Table S2. Impact of endothelial cell removal on function of aorta and 
femoral arteries from control mice. 
Data are mean+s.e.mean. ACh, acetylcholine, ET-1, endothelin-1, KPSS, high (125mM) potssium 
physiological salt solution. PE, phenylephrine. *P<0.05 compared with intact artery. Emax, 
maximum contraction; pD2, -log EC50. 
 
   
Drug Measurement Aorta 
(Intact) 
Aorta 
(Denuded) 
Femoral 
Artery 
(Intact) 
Femoral 
Artery 
(Denuded) 
PE N 3 3 3 3 
 pD2 7.1 ± 0.2 7.3 ± 0.2 5.8 ± 0.1  6.5 ± 0.1*  
 Emax (%) 80.3 ± 5.5 199.8 ± 11.4* 100.3 ± 6.2 94.6 ± 4.5 
 Emax (mN/mm) 3.92 ± 0.34 3.48 ± 0.19 2.35 ± 0.20 1.61 ± 0.14 
      
ACh N 3 3 3 3 
 -logIC50 7.4 ± 0.4 7.9 ± 1.0 7.4 ± 0.2 6.5 ± 6.1 
 Emax (%) 62.7 ± 7.1 31.5 ± 7.3 108.6 ± 5.7 19.5 ± 11.8* 
      
ET-1 N 3 3 3 3 
 pD2 8.5 ± 0.4   8.0 ± 0.2 8.2 ± 0.2 8.4 ± 0.1 
 Emax (%) 53.4 ± 8.4 74.3 ± 4.7 95.2 ± 4.5 89.6 ± 4.2 
 Emax (mN/mm) 1.78 ± 0.42 1.23 ± 0.20 2.51 ± 0.36 2.35 ± 0.46 
      
KPSS N 4 4 4 4 
 Emax (mN/mm) 2.91 ± 0.58 2.03 ± 0.43 3.21 ± 1.36 2.56 ± 1.23 
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Supplementary Table S3 Impact of deletion of ETB from vascular smooth muscle on 
functional responses of femoral arteries. 
Data are mean+s.e.mean. SM ETB KO, selective deletion of the endothelin B receptor from smooth 
muscle. ACh, acetylcholine, ET-1, endothelin-1, KPSS, high (125mM) potassium physiological 
salt solution. PE, phenylephrine. *P<0.05, †P<0.01, ‡P<0.005 compared with intact artery. Emax, 
maximum contraction; pD2, -log EC50. 
 
   
Drug Measurement Wild Type 
(Intact) 
Wild Type 
(Denuded) 
SM ETB 
KO 
(Intact) 
SM ETB KO 
(Denuded) 
PE N 6 7 7 7 
 pD2 5.7 ± 0.1 6.0 ± 0.1 5.6 ± 0.1 6.1 ± 0.1 
 Emax(%) 88.9 ± 3.2 94.2 ± 3.2 91.9 ± 4.4 102.8 ± 3.8 
 Emax (mN/mm) 3.99 ± 0.35 2.05 ± 0.26 3.48 ± 0.25 2.37 ± 0.20 
      
ACh N 5 6 6 6 
 -logIC50 8.0 ± 0.6 6.8 ± 0.4† 7.9 ± 0.5 7.2 ± 0.6* 
 Emax(%) 120.1 ± 
10.2 
57.8 ± 6.4* 120.9 ± 9.6 22.5 ± 3.2‡ 
      
ET-1 N 6 7 7 7 
 pD2 7.8 ± 0.2 7.8 ± 0.3 7.9 ± 0.2 8.0 ± 0.2 
 Emax(%) 97.4 ± 7.9 112.9 ± 3.5 105.4 ± 5.8 130.3 ± 5.4 
 Emax (mN/mm) 4.03 ± 0.42 2.46 ± 0.40 4.04 ± 0.33 2.99 ± 0.27 
      
KPSS N 6 7 7 7 
 Emax (mN/mm) 4.44 ± 0.81 1.99 ± 0.64* 3.84 ± 0.52 2.38 ± 0.54 
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Supplementary Table S4. Impact of endothelin receptor antagonism on endothelin-1-
mediated contraction of murine mesenteric arteries. 
 Antagonist
Measurement Vehicle ETA ETB ETA/B 
N 7 3 3 3 
pD2 8.2+0.5 7.4+0.2* 8.0+0.1 7.0+0.1* 
Emax (mN/mm) 2.4+0.7 2.4+1.3 3.4+0.5 2.3+1.0 
Emax (% KPSS) 105+17 102+21 111+10 75+30 
Data are mean+s.e.mean. *P<0.05 compared with Vehicle. Emax, maximum contraction; 
pD2, -log EC50. 
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Supplementary Table S5. Incubation induces ETB-mediated contraction in mouse 
mesenteric arteries. 
Drug Measurement Incubation 
  Day 0 Day 1 Day 5
KPSS N 7 7 3 
 Emax (mN/mm) 2.47+0.80 2.42+0.68 1.40+1.03 
PE N 7 7 3 
 pD2 5.90+0.25 5.71+0.24 5.65+0.44 
 Emax (mN/mm) 2.33+0.70 2.89+1.30 1.04+1.24 
 Emax (% KPSS) 97.8+15.6 114.1+25.1 111.7+91.7 
S6c N 7 7 3 
 pD2 --- 8.75+0.19 8.73+0.05 
 Emax (mN/mm) 0.13+0.16 1.13+1.08* 0.82+0.60† 
 Emax (% KPSS) 6.4+7.6 40.2+32.6* 94.5+75.4† 
ET-1 N 7 5 3 
 pD2 8.24+0.53 8.50+0.40 8.54+0.25 
 Emax (mN/mm) 2.45+0.73 3.79+0.88* 1.35+1.22* 
 Emax (% KPSS) 105.4+17.8 164.1+16.4* 132.8+87.6 
Data are mean+s.e.mean.. ET-1, endothelin-1, KPSS, high (125mM) potassium physiological 
salt solution, PE, phenylephrine, S6c, sarafotoxin s6c. *P<0.05 compared with Day 0. 
†P<0.05 compared with Day 1. Emax, maximum contraction; pD2, -log EC50. 
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Supplementary Table S6. Impact of endothelin receptor antagonism on sarafotoxin s6c-
mediated contraction of murine mesenteric arteries. 
  Antagonist
Timepoint Measurement Vehicle ETA ETB ETA/B 
Day 0 N 7 3 3 3 
 pD2 NC NC NC NC 
 Emax (mN/mm) 0.13+0.16 0.01+0.01 0.03+0.03 0.04+0.04 
 Emax (% KPSS) 6.4+7.6 0.90+1.3 1.0+06 1.2+1.2 
Day 1 N 7 3 3 3 
 pD2 8.75+0.19 8.41+0.17* NC NC 
 Emax (mN/mm) 1.13+1.08 2.63+0.90 0.01+0.01 0.00+0.01 
 Emax (% KPSS) 40.2+32.6 73.3+17.75 0.7+0.4* 0.4+0.4* 
Day 0, fresh arteries; Day 1, 24 h incubation. Data are mean+s.e.mean.. NC, not calculated. 
*P<0.05 compared with Vehicle. Emax, maximum contraction; pD2, -log EC50. 
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Supplementary Table S7. The impact of vascular cell selective deletion of murine vascular 
ETB receptors (compared with wild type controls). 
Measurement EC ETB KO* SMC ETB KO 
Body Weight NSD1, 2, 3, 4 NSD 
Organ Weight NSD1, 2,4 NSD 
Plasma [ET-1]   
     Basal Increased2 NSD 
     High salt diet + ETB 
antagonist 
 NSD 
Blood Pressure (basal)   
     Basal NSD2 Small (4mmHg) Increase  
     High salt diet NSD2 Small (4mmHg) Increase 
     High salt diet + ETB 
antagonist. 
NSD2 NSD 
Heart Rate NSD2 Reduced 
Neointimal Proliferation NSD1, 4 NSD 
ETB-mediated contraction   
     Trachea NSD1, 2,4 Reduced 
     Mesenteric Vein N/A Abolished 
     Mesenteric Artery N/A Induction Abolished 
     Femoral Artery N/A N/A 
ACh-mediated relaxation   
     Aorta Impaired2  
     Femoral Artery NSD1, 4 NSD 
ET-1-mediated contraction   
     Femoral Artery NSD1, 4 NSD 
PE-mediated contraction   
     Femoral Artery NSD1,4 NSD 
From previous investigations. 1Kirkby et al., 2012, 2Bagnall et al., 2006; 3Kelland et al., 
2010; 4Kirkby, N.S. PhD Thesis Edinburgh 2009. ACh, acetylcholine; ET-1, endothelin-1; 
PE, phenylephrine; ETB, endothelin B receptor; NSD, No significant difference compared 
with Wild Type; N/A, not assessed. 
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Supplementary Figure S1 
Miller et al. 
(a) Smooth Muscle Actin (αSMA) (b) Macrophages (Mac 2) 
(c) Collagen (picrosirius red) 
SMETB KO Wild Type SMETB  Wild Type 
L 
NI 
L 
NI 
Supplementary Figure  S1. Identification of smooth muscle, macrophages and collagen in 
neointimal lesions. 
Compositional analysis of neointimal lesions induced by wire injury in smooth muscle selective ETB KO 
(SMETBKO) and wild type mouse femoral arteries showing the presence of immunoreactivity for (a) 
Smooth muscle actin (brown) and (b) Macrophages (Mac 2; brown). (c) Picrosirius red staining (pink) 
identified collagen in the neointima and media. Scale bar = 100μm. L, Lumen, NI, neointima. 
SMETB KO Wild Type 
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Supplementary Figure S2 
Miller et al. 
(a) (d) 
(b) 
(e) 
(c) 
Supplementary Figure S2. Impact of endothelial cell removal on functional responses of 
murine aorta and femoral artery. 
Aorta (a, b, c) and femoral arteries (d, e, f) from adult male C57Bl/6j mice relaxed in 
response to acetylcholine (ACh) (a, d) and contracted in response to phenylephrine (PE) (b, 
e) and endothelin‐1 (ET‐1) (c, f). Removal of the endothelium abolished ACh‐mediated 
relaxation and substantially increased aortic, but not femoral arterial, contraction to PE. It 
did not, however, alter ET‐1 mediated contraction in aorta or in femoral artery. Symbols 
represent mean+s.e.mean for n= 3 mice. *P<0.05; **P<0.01; ***P<0.001. 
(f) 
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Supplementary Figure S3 
Miller et al. 
(a) 
  
Supplementary Figure S3. Selective deletion of ETB from the smooth muscle does not 
alter femoral artery function. 
Concentration‐response curves for (a) phenylephrine (PE), (b) endothein‐1 (ET‐1) and (c) 
acetylcholine (ACh) were generated in femoral arteries from control (FF‐‐) and SM ETB 
knockout (FFSm22Cre) mice. Responses to ACh were obtained following sub‐maximal 
contraction with PE. Deletion of ETB had no effect on the responses produced by these 
agonists. Symbols represent mean+s.e.mean for n=6‐7mice. 
(c) 
(b) 
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Supplementary Figure S4 
Miller et al 
Supplementary Figure S4. Endothelin‐1‐mediated contraction of murine mesenteric 
arteries is mediated by ETA receptors. 
In murine mesenteric arteries endothelin‐1 (ET‐1)‐mediated contraction was shifted 
dramatically to the right by incubation with selective ETA (BQ123; 100nM) or mixed 
ETA/B antagonism, but selective ETB antagonism (A‐192621; 100nM) had a much 
smaller effect. Symbols represent mean+s.e.mean, n=3‐7. *P<0.05 compared with 
Vehicle. 
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Supplementary Figure S5 
Miller et al. 
(b) (c) 
(a) 
Supplementary Figure S5. Neointimal lesion formation does not alter functional 
responses of mouse femoral artery. 
Mouse femoral arteries isolated 28 days after ligation showed unaltered responses 
to (a) phenylephrine (PE), (b) acetylcholine (ACh) or, (c) sodium nitroprusside (SNP) 
Data are mean+s.e.mean, n=3‐6. 
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SMETB deletion 
Bodyweight 
Organ weight 
Plasma [ET‐1] 
Blood Pressure 
Heart Rate (Reduced) 
ETB Mediated Contraction 
 ‐ Trachea (Impaired) 
 ‐ Mesenteric Vein (Abolished) 
 ‐ Mesenteric Artery (Abolished) 
Salt‐induced Hypertension 
Unchanged 
ETB Antagonist‐induced Hypertension 
Increased 
Reduced/Impaired 
Neointimal Lesion Formation 
Supplementary Figure S6 
Miller et al. 
Supplementary Figure S6. Schematic summary of the effects of smooth muscle cell 
specific deletion of the Endothelin B receptor (SM ETB KO) in mice. 
